Zili Xiao
Bristol-Myers Squibb (Germany)(DE)Southwest Petroleum University(CN)Fudan University(CN)Bristol-Myers Squibb (United States)(US)Huadong Hospital(CN)Bristol-Myers Squibb (Sweden)(SE)
Publications by Year
Research Areas
Crystallization and Solubility Studies, X-ray Diffraction in Crystallography, Crystallography and molecular interactions, Cytokine Signaling Pathways and Interactions, Quinazolinone synthesis and applications
Most-Cited Works
- → Design and synthesis of pfmrk inhibitors as potential antimalarial agents(2001)85 cited
- → Effects of Putative Hydroxylated Thalidomide Metabolites on Blood Vessel Density in the Chorioallantoic Membrane (CAM) Assay and on Tumor and Endothelial Cell Proliferation.(2002)63 cited
- → Discovery and Development of 5-[(5S,9R)-9- (4-Cyanophenyl)-3-(3,5-dichlorophenyl)-1- methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non- 7-yl-methyl]-3-thiophenecarboxylic Acid (BMS-587101)A Small Molecule Antagonist of Leukocyte Function Associated Antigen-1(2006)51 cited
- → Acridone-Based Inhibitors of Inosine 5‘-Monophosphate Dehydrogenase: Discovery and SAR Leading to the Identification of N-(2-(6-(4-Ethylpiperazin-1-yl)pyridin-3-yl)propan-2-yl)-2- fluoro-9-oxo-9,10-dihydroacridine-3-carboxamide (BMS-566419)(2007)49 cited
- → Small Molecule Antagonist of Leukocyte Function Associated Antigen-1 (LFA-1): Structure−Activity Relationships Leading to the Identification of 6-((5S,9R)-9-(4-Cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]nonan-7-yl)nicotinic Acid (BMS-688521)(2010)43 cited